CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 266,787 shares of the company’s stock after buying an additional 6,899 shares during the period. Massachusetts Financial Services Co. MA owned 0.40% of CG Oncology worth $8,422,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in CGON. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology in the first quarter valued at approximately $492,000. Capstone Investment Advisors LLC purchased a new position in shares of CG Oncology during the 1st quarter worth $806,000. TimesSquare Capital Management LLC acquired a new stake in shares of CG Oncology during the first quarter worth $9,837,000. Vanguard Group Inc. purchased a new stake in shares of CG Oncology in the first quarter valued at $97,678,000. Finally, Ameritas Investment Partners Inc. acquired a new position in CG Oncology in the first quarter valued at $102,000. 26.56% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $35.36, for a total value of $23,000,088.80. Following the completion of the sale, the director now owns 586,982 shares of the company’s stock, valued at $20,755,683.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Analyst Ratings Changes

CGON has been the topic of a number of research analyst reports. Roth Mkm initiated coverage on CG Oncology in a research note on Tuesday, August 27th. They issued a “buy” rating and a $65.00 price target on the stock. Roth Capital upgraded shares of CG Oncology to a “strong-buy” rating in a report on Tuesday, August 27th. Bank of America began coverage on shares of CG Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $65.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research note on Tuesday, September 17th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $64.17.

CG Oncology Price Performance

Shares of CGON stock opened at $39.00 on Friday. The company’s fifty day simple moving average is $35.29 and its 200-day simple moving average is $35.32. CG Oncology, Inc. has a 52 week low of $25.77 and a 52 week high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.14. The company had revenue of $0.11 million during the quarter. As a group, research analysts forecast that CG Oncology, Inc. will post -1.47 earnings per share for the current year.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.